Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker
Current Medicinal Chemistry · 2024
DOI: 10.2174/0929867330666230516102017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Medicinal Chemistry, 2024. Verfasst von Zeenat Mirza. Beteiligte Einrichtung: King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Survivin, Breast Neoplasms, Biomarkers, Tumor, Transcriptome. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 56 Literaturangaben. Gefördert von: King Abdulaziz University, Deanship of Scientific Research (DSR), King Abdulaziz University.
Abstract (Originalsprache)
Background
Breast cancer is the leading cause of cancer-related mortality among women worldwide. Advanced stages are usually obstinate with chemotherapy, resulting in a poor prognosis; however, they are treatable if diagnosed early.
Objective
Identifying biomarkers that can detect cancer early or have therapeutic significance is imperative.
Methods
Herein, a comprehensive bioinformatics-based transcriptomics study of breast cancer for identifying differentially expressed genes (DEGs), followed by a screening of potential compounds by molecular docking, was performed. Genome-wide mRNA expression data of breast cancer patients (n=248) and controls (n=65) were retrieved from the GEO database for meta-analysis. Statistically significant DEGs were used for enrichment analysis based on ingenuity pathway analysis and protein-protein network analysis.
Results
A total of 3096 unique DEGs (965 up-regulated and 2131 down-regulated) were mapped as biologically relevant. The most upregulated genes were COL10A1, COL11A1, TOP2A, BIRC5 (survivin), MMP11, S100P, RARA, and the most downregulated genes were ADIPOQ, LEP, CFD, PCK1 and HBA2. Transcriptomic and molecular pathway analyses identified BIRC5/survivin as a significant DEG. Kinetochore metaphase signaling is recognized as a prominent dysregulated canonical pathway. Protein-protein interaction study revealed that KIF2C, KIF20A, KIF23, CDCA8, AURKA, AURKB, INCENP, CDK1, BUB1 and CENPA are BIRC5-associated proteins. Molecular docking was performed to exhibit binding interactions with multiple natural ligands.
Conclusion
BIRC5 is a promising predictive marker and a potential therapeutic target in breast cancer. Further large-scale studies are required to correlate the significance of BIRC5 in breast cancer, leading to a step toward the clinical translation of novel diagnostic and therapeutic options.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia.
ORCID-Profile: Zeenat Mirza
Förderung
- King Abdulaziz University
- Deanship of Scientific Research (DSR), King Abdulaziz University
Zitieren
APA
Mirza, Z. (2024). Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker. Current Medicinal Chemistry. https://doi.org/10.2174/0929867330666230516102017
Vancouver
Mirza Z. Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker. Current Medicinal Chemistry. 2024. doi:10.2174/0929867330666230516102017
BibTeX
@article{Mirza2024,
author = {Mirza, Zeenat},
title = {Integrated High-throughput Transcriptomic Data Identifies Survivin as a Potential Breast Cancer Therapeutic Biomarker},
journal = {Current Medicinal Chemistry},
year = {2024},
doi = {10.2174/0929867330666230516102017}
}
EUVIMED